

October 26, 2026

Dear Pharmaceutical Manufacturer:

Arizona's Medicaid Program, the Arizona Health Care Cost Containment System (AHCCCS), has contracted with Prime Therapeutics to secure supplemental rebates for preferred agents on the AHCCCS Drug List. The AHCCCS Drug List is utilized by both the Fee-For-Service and Managed Care Organization (MCO) programs.

The intent of AHCCCS is to accrue rebates on both Fee-For-Service and Managed Care utilization for preferred agents under the AHCCCS drug list which is managed by the AHCCCS for covered outpatient drugs dispensed to persons eligible in Arizona for Medicaid, the Children's Health Insurance Program and to persons with Serious Mental Illness, as defined in A.R.S. 36-550, who qualify for state funded care under A.R.S. 36-3408. The AHCCCS supplemental rebate agreement, drafted with the express purpose of establishing a single drug list and described further in section 2.1 of the ARIZONA HEALTH CARE COST CONTAINMENT SYSTEM SUPPLEMENTAL DRUG-REBATE AGREEMENT (SRA), was approved by CMS on May 28, 2015.

SRA 2.1 It is the intent of this Agreement that the State will receive Supplemental Rebates, in addition to the rebates received under Manufacturer's CMS Agreement, pursuant to Section 1927 of the Social Security Act (42 U.S.C. §1396r-8), for the Manufacturer's Supplemental Covered product(s) quarterly utilization in the Arizona Medicaid Program, including all Fee-For-Service and Managed Care beneficiaries, in which there is Medicaid federal financial participation. The parties also intend for this Agreement to meet the requirements of federal law at Section 1927 of the Social Security Act (42 U.S.C. §1396r-8).

The next P&T Meeting is scheduled for January 26, 2027, and will be held virtually beginning at Noon and ending at 5 PM. More information can be found on the [AHCCCS Pharmacy webpage](#).

At this time, supplemental rebate offers are **not** requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee:

- Antidepressants, Other
- Bladder Relaxant Preparations
- Bone Resorption Suppression and Related Agents
- Bronchodilators, Beta Agonists
- Erythropoiesis Stimulating Proteins
- Enzyme Replacement, Gaucher Disease
- Hypoglycemics, SGLT2s
- Immune Globulins
- Oncology, Oral – Hematologic (Brands Over Generics only)
- Ophthalmics, Anti-inflammatory/Immunomodulators
- Oral and Inhaled Pulmonary Arterial Hypertension Agents
- Otic Antibiotics
- Thrombopoiesis Stimulating Agents
- Ulcerative Colitis

At this time, supplemental rebate offers **are** requested for the following products and therapeutic categories which will be reviewed at the Pharmacy and Therapeutics Committee:

- Anticonvulsants
- IgA Nephropathy Agents
- Pituitary Suppressive Agents, LHRH

New Drug Reviews

- Lipfendra
- Adquey
- Lisraya
- Juvmo

Manufacturer representatives and the public may use the link below to submit a request to provide oral or written testimony for medications listed under New Drug Reviews above and also for drugs listed in the supplemental rebate therapeutic classes. Submitting public testimony shall be in accordance with the [AHCCCS P&T Operational Policy](#) which can be located under Arizona on the Prime Therapeutics website.

A link to the Prime Therapeutics Government Solutions web page is provided below:
<https://www.primetherapeutics.com/en/single-state-programs>

We look forward to you attending the virtual AHCCCS P&T Committee Meeting on January 26, 2027.

Sincerely,

A handwritten signature in black ink, appearing to read 'Theresa Costales', followed by a comma and the letters 'MD'.

Theresa Costales
Chief Medical Officer